<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/624FC0B7-618B-4A6A-B844-5A775EE3819E"><gtr:id>624FC0B7-618B-4A6A-B844-5A775EE3819E</gtr:id><gtr:name>Duke University Health System</gtr:name><gtr:address><gtr:line1>3100 Tower Blvd. Suite 1008</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/624FC0B7-618B-4A6A-B844-5A775EE3819E"><gtr:id>624FC0B7-618B-4A6A-B844-5A775EE3819E</gtr:id><gtr:name>Duke University Health System</gtr:name><gtr:address><gtr:line1>3100 Tower Blvd. Suite 1008</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0D055105-4149-452C-BEF6-C180B163A684"><gtr:id>0D055105-4149-452C-BEF6-C180B163A684</gtr:id><gtr:firstName>Ye</gtr:firstName><gtr:otherNames>Htun</gtr:otherNames><gtr:surname>Oo</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002552"><gtr:id>1900C8BD-3A32-4FC2-B870-984EC1A7C05E</gtr:id><gtr:title>Intrahepatic signals involved in the recruitment and differentiation of IL-17 secreting T cells and Regulatory T cells i</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002552</gtr:grantReference><gtr:abstractText>Liver disease is increasing in Western countries and there are nowhere near enough organ donors to treat the number of patients with end-stage liver disease. Chronic hepatitis leads to scarring (cirrhosis) and liver failure and the only effective treatment is liver transplantation. Lymphocytes are a type of white blood cell and an important part of the body?s immune system. They normally fight infections but if they persist or become inappropriately activated they can cause liver injury as part of chronic hepatitis or inflammation that leads to scarring and liver failure. Lymphocytes are directed to sites of liver inflammation by molecules called chemokines that are produced in response to inflammation. These chemokines are specific in that they can direct the entry/ recruitment of particular groups of lymphocytes to specific tissues. These groups include damaging effector lymphocytes and regulatory cells which damp down inflammation leading to resolution of damage. The outcome of liver injury depends on the balance between these inflammatory and anti-inflammatory regulatory lymphocytes which in turn will be determined by a) which types of cells are recruited to the liver from blood b) signals within the liver that shape the survival, activation and expansion of specific lymphocytes. Shifting the balance towards anti-inflammatory regulatory cells may prevent liver inflammation and promote resolution thereby reversing progression to fibrosis/cirrhosis. We would like to investigate the molecular signals involved and then exploit our knowledge to develop novel therapeutic approaches using anti-inflammatory regulatory lymphocytes as cell therapy to treat chronic liver diseases.</gtr:abstractText><gtr:technicalSummary>Hypothesis

Intrahepatic signals regulate the balance of effector regulatory networks in the human liver by shaping the recruitment and differentiation of functional t cells subsets. 
The outcome of liver injury depends on the balance between inflammatory effector and anti-inflammatory response. In the proposed fellowship I will investigate this balance in human inflammatory liver disease by 1) defining signals that recruit and position Treg, Th1, Th22 and Th17 cells within the inflamed liver 2) defining the effect of the liver microenvironment and particularly dendritic cells and stromal cells on T cell survival and differentiation. I will also study the trafficking of autologous regulatory T cells after intravenous injection into patients with liver disease using MRI to determine homing and survival of Treg in vivo. 
Aims and Design
1. Intra-hepatic signals regulate T cell subset recruitment to the human liver
I will use flow-based assays to determine endothelial and stromal cell factors that promote selective recruitment of effector versus regulatory T cells to the human liver. I will develop a human tissue assay to study post-endothelial migration of T cells in viable liver ex vivo in real-time. T cells and liver cells will be labelled with different fluorchromes and the migration of T cells through tissue tracked using Nipkov spinning-disc confocal microscopy.
2. Hepatic do stromal cells and dendritic cells regulate T cell survival and differentiation
I will study intrahepatic signals including those mediated through stromal cells that modulate T cell survival and differentiation using co-culture assays in which different cytokines and differentiation factors are added. The survival, plasticity and differentiation of Th1, Th17 and Th22 cells will be studied in Prof Paul Klenerman?s laboratory in Oxford and the role of specific Th17 and Th122 differentiation factors will involve a collaboration with Dr Mark Veldhoen in Cambridge. 
3. Homing of regulaty T cells in patients with autoimmune liver disease
The Birmingham NIHR Liver BRU has facilities and expertise to carry out cell therapy clinical trials. Within the BRU we are developing MRI to track infused cells in patients. I will use this technique to track infused autologous Treg isolated from the blood of patients with autoimmune liver disease. I have defined GMP-compliant methods for Treg isolation I will now optimise MRI labelling in collaboration with Prof Hannon (Centre for Physical Sciences of Imaging in the Biomedical Sciences) who has developed novel MRI labels for cell imaging. I will record migration and localization of infused Treg using our research-dedicated 3T MRI. 
This project will provide an outstanding opportunity to continue my development as a translational researcher in immunology putting me at the forefront of cell-based therapy for liver disease.</gtr:technicalSummary><gtr:fund><gtr:end>2018-01-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1174830</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Hepatology</gtr:department><gtr:description>Osteopontin promote fiborsis progression in NAFLD</gtr:description><gtr:id>2B3FBA94-059A-4751-A7DE-D64B1F4BD37F</gtr:id><gtr:impact>Osteopontin is induced by Hedgehog Pathway Activation and Promotes Fibrosis Progression in Nonalcoholic Steatohepatitis. Hepatology Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in non-alcoholic steatohepatitis. Hepatology 2010 (in press DOI: 10.1002/hep.23998).</gtr:impact><gtr:outcomeId>h7yBzfVNfGo-1</gtr:outcomeId><gtr:piContribution>Immunohistochemical staining of Osteopontin in human liver tissue</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Peter Medawar Building for Pathogen Research</gtr:department><gtr:description>Th17 and Tc17 in Human Hepatitis C infection</gtr:description><gtr:id>46C0E84F-871B-4EAA-ACD0-46E751F1CEB3</gtr:id><gtr:impact>Analysis of CD161 expression on human CD8+ T cells defines a functional subset with tissue-homing properties; (Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3006-11)</gtr:impact><gtr:outcomeId>093CF43D799-1</gtr:outcomeId><gtr:partnerContribution>Understanding of IL-17 secreting lymphocytes in human hepatitis C liver</gtr:partnerContribution><gtr:piContribution>Phenotyping of freshly isolated Liver infiltrating lymphocytes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Th17 and AHR ligands</gtr:description><gtr:id>E508726C-BE3E-4E88-AE02-49B08A61F8A7</gtr:id><gtr:impact>Not started yet</gtr:impact><gtr:outcomeId>ZJXFDMXihqt-1</gtr:outcomeId><gtr:piContribution>Plan to go across to Institute to explore AhR ligands in liver</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Peter Medawar Building for Pathogen Research</gtr:department><gtr:description>HCV vaccination</gtr:description><gtr:id>8F0B1675-857C-421C-B274-93CD52814161</gtr:id><gtr:impact>Still in recruitment. Five patients from Birmingham vaccinated</gtr:impact><gtr:outcomeId>cUmB6Bppdho-1</gtr:outcomeId><gtr:piContribution>Second UK centre for HCV Therepeutic vaccination in Genotype 1 patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Human Tissue Biorepository</gtr:department><gtr:description>Gamma Delta cells in HCV</gtr:description><gtr:id>EFDC0A01-EF0C-4226-B373-3293AB2E0AC7</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>kM7i1zpYKN5-1</gtr:outcomeId><gtr:partnerContribution>Cellular culture and protein expression</gtr:partnerContribution><gtr:piContribution>To expend intracellular T cell network experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Accumulation of NKT cells in Progressive Non Alcoholic Steato Hepatitis</gtr:description><gtr:id>717B4C99-99D9-45E7-B4A6-651440ABB075</gtr:id><gtr:impact>Accumulation of NKT cells in progressive NASH,. (Hepatology. 2010 Jun;51(6):1998-2007)</gtr:impact><gtr:outcomeId>8C195E10E06-1</gtr:outcomeId><gtr:partnerContribution>Understanding of NKT in human liver disease</gtr:partnerContribution><gtr:piContribution>Phenotyping of Human NKT population in normal and diseaase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Peter Medawar Building for Pathogen Research</gtr:department><gtr:description>CD8aa and IL-22 cells in HCV</gtr:description><gtr:id>0DF060B2-D728-4DF1-923B-843506D62B5D</gtr:id><gtr:impact>? Lucy J Walker, Yuhoi H Kang, Matthew O Smith, Hannah Tharmalingham, Ye Htun Oo, Thomas J Scriba, Willem A Hanekom, Georg M Lauer, David H Adams , Eleanor Barnes, Paul Klenerman. Human CD8aaT cells are a CD161++ subset with distinct functional characteristics. (submitted to Gastroenterology)
? Yu-Hoi Kang, Eva Billerbeck, Vicki Fleming, Stefanie Grafmueller, Lucy Walker, Chris B. Willberg, Eleanor J. Barnes, Anisha Bhagwanani, Ye Htun Oo, Hubert E Blum, David H. Adams, Robert Thimme, Paul Klenerman. Recruitment of IL-22 secreting CD4+ T cells to the liver in hepatitis C. (submitted to Hepatology)</gtr:impact><gtr:outcomeId>beChUakD9Bu-1</gtr:outcomeId><gtr:piContribution>Liver infiltrating lymphocytes isolation and phenotyping</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Sceince Festival to Public in Westmidlands</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C5514AA4-2B63-44BF-8823-5E182B0B5682</gtr:id><gtr:impact>Disseminate information to public on HCV vaccination work which is now being carried out in collaboration with Oxford

Awareness of public to liver disease</gtr:impact><gtr:outcomeId>dkm1ge9VN8v</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gordon Immunology Conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>15CE317D-4582-41A6-8366-1DDC0BD4DFD7</gtr:id><gtr:impact>Human Liver Infiltraing Regulator T cells

Collboration</gtr:impact><gtr:outcomeId>FD67D3D505D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Association of Study of Liver Disease Annual Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>71569BB5-8485-4794-AE21-03104DE1D68A</gtr:id><gtr:impact>Oral Presentation in 2008 on Regulatory T cell work Presendential Plenary Presentation in 2009 on Th17 work

Collaboration</gtr:impact><gtr:outcomeId>66F6132365D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Adhesion Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5CF6CA68-4FA2-4E08-9F2F-B0D2C83B7EFC</gtr:id><gtr:impact>Oral presentation on Regularoty T cells role in human liver inflammation

Collaboration</gtr:impact><gtr:outcomeId>FFF6FF50375</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Research Society Annual Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F834D79F-B821-4420-9C08-FE9600D12C68</gtr:id><gtr:impact>Poster presentation on human liver infiltrating Treg

Collaboration</gtr:impact><gtr:outcomeId>DCF7FC43526</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association of Physician Annual Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FE2F9485-D9A7-48DD-AEEA-CECACBEDE981</gtr:id><gtr:impact>Oral presentation on Distinct role of Regulatory T cells in inflamed human liver

Clinical cell based therapy potentail</gtr:impact><gtr:outcomeId>D95DA613BDF</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>47B476DD-8E9E-4524-A0A3-4A214A630071</gtr:id><gtr:impact>Liver Transplantation ethics to grammer school students

Spread message on important of liver disease, transplantion and liver research</gtr:impact><gtr:outcomeId>htEzMcn72xj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association of Study of Liver Disease Annual Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>209AEBA0-3CBA-4DB0-A71F-F6EA2033BB4D</gtr:id><gtr:impact>Poster presentation at BASL meeting

Collaboration and understanding the impact of therapeutic potential for Regulatory T cells</gtr:impact><gtr:outcomeId>7EEB61EC1E0</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EASL Immunology Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F6980499-BA25-4361-9266-80B0A65428CC</gtr:id><gtr:impact>Phenotype and recruitment of Regulatory T cells in inflamed human liver

Collaboration, Learning new methodolgy</gtr:impact><gtr:outcomeId>4CAE507DA7F</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MAIR conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6D191764-D5B0-491D-9CF4-9F20AFA5D843</gtr:id><gtr:impact>Poster presentation on human Treg work

collaboration</gtr:impact><gtr:outcomeId>0BAB7E9FF9B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Student Teaching on Immune Tolerance 2006,2007,2008,2009</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A183E362-DF19-4589-A501-138F1134FEF4</gtr:id><gtr:impact>Part of Medical Student's teaching on Immunology, Autoimmune hepatitis and role of Regulatory T cells

Student's understanding of Immunological tolerance and consequence of brakdown in toleranc</gtr:impact><gtr:outcomeId>4DC53CD8EA1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Students and BMed Science teaching 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C8438AF9-DDB3-47E6-A39E-D85ECFEE026C</gtr:id><gtr:impact>local teaching programme participation

To find BMed science student for lab project.</gtr:impact><gtr:outcomeId>B38pDZpAMX5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>86000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IL-17 secreting cells in human liver</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>B37530CE-9497-4F72-BDE9-2FA8EB28F9CF</gtr:id><gtr:outcomeId>67CFDA7C51A0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Positioning and funciton of Human Th17 cell in inflamed liver (University Hospital Birmingham Charity)</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Queen Elizabeth Hospital Birmingham Charity (QEHB)</gtr:fundingOrg><gtr:id>28C5074B-FF2C-4CAF-8A7C-023D878CC7F6</gtr:id><gtr:outcomeId>h8j9RqUGXoo0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Lab based investigation at present and plan to move to translational proof of concept of Treg tracking to human liver in future.
Currently generating GMP grade Treg for future cell therapy.</gtr:description><gtr:id>0D3A3803-B361-4BE8-B80D-B0921459516F</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>tA6KgFTaM5X</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Regulatory T cells in the human liver</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E098F63C-2B96-46DD-AA99-D10BE1EAB9F2</gtr:id><gtr:title>Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy.</gtr:title><gtr:parentPublicationTitle>Canadian journal of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84fcea8d3b0649ebc2a5600412a364bb"><gtr:id>84fcea8d3b0649ebc2a5600412a364bb</gtr:id><gtr:otherNames>Than NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2291-2789</gtr:issn><gtr:outcomeId>58bd476e6b8208.81944118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F54B61C-FE65-4301-A32C-BE209911D499</gtr:id><gtr:title>Innate immune cells in liver inflammation.</gtr:title><gtr:parentPublicationTitle>Mediators of inflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2ec17573a7d601b84c252ca07eecde4"><gtr:id>e2ec17573a7d601b84c252ca07eecde4</gtr:id><gtr:otherNames>Liaskou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0962-9351</gtr:issn><gtr:outcomeId>pm_15970_20_22933833</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0947CE83-B5B4-446B-BD7B-1C79E2C60883</gtr:id><gtr:title>CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15970_20_22796894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>773BF583-B030-4625-B08A-E4061317F435</gtr:id><gtr:title>Low-dose interleukin-2 promotes STAT-5 phosphorylation, Tsurvival and CTLA-4-dependent function in autoimmune liver diseases.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>58bd46abc6bf40.30212643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F591580-C9AD-4A59-820C-4288CD6B4EFB</gtr:id><gtr:title>Human MAIT and CD8aa cells develop from a pool of type-17 precommitted CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e010a90f68a03e6f502ca741eaf42f"><gtr:id>01e010a90f68a03e6f502ca741eaf42f</gtr:id><gtr:otherNames>Walker LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>LqsGJ23aESP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AD13BC4-32FB-4B30-8A48-127EFBF3D6B8</gtr:id><gtr:title>Erratum to: The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019).</gtr:title><gtr:parentPublicationTitle>BMC surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/133c1ffa130e108ab83b5a1b0f5627f5"><gtr:id>133c1ffa130e108ab83b5a1b0f5627f5</gtr:id><gtr:otherNames>Gardenbroek TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2482</gtr:issn><gtr:outcomeId>56dd9759974e06.34980084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0031934-C23E-4409-995E-691B30A019AB</gtr:id><gtr:title>Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d70dc7bb49a750d51b5f50e44caa910f"><gtr:id>d70dc7bb49a750d51b5f50e44caa910f</gtr:id><gtr:otherNames>Kelly C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dd975a2a6d38.48060408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A95C924E-86BA-4A4A-B756-B8238CDE4676</gtr:id><gtr:title>CD161(+)CD4(+) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-?.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bf7d27c642565afc59f9dd9ee3dfc5b"><gtr:id>9bf7d27c642565afc59f9dd9ee3dfc5b</gtr:id><gtr:otherNames>Kang YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>doi_15970_2012_00346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52096891-3C0F-4E80-85C5-60B6C7747FF0</gtr:id><gtr:title>Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_15970_20_22218690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFAF68E3-FF99-41B3-950F-662259321E2F</gtr:id><gtr:title>Regulatory T cells and autoimmune hepatitis: what happens in the liver stays in the liver.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>545a5b67e58c96.14963026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BC9D1EE-BBEF-4B89-90F9-87F3F2AF6915</gtr:id><gtr:title>Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ea48fd39e56eb350fb59f5ff1d6e999"><gtr:id>5ea48fd39e56eb350fb59f5ff1d6e999</gtr:id><gtr:otherNames>Krishnamoorthy TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>56dd975a7017e7.32577484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34B9CC9A-40F3-4BF0-93EC-7A48DAA1D19F</gtr:id><gtr:title>Recruitment mechanisms of primary and malignant B cells to the human liver.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd20de4d5c14af8cc708d7b67c01f07e"><gtr:id>bd20de4d5c14af8cc708d7b67c01f07e</gtr:id><gtr:otherNames>Shetty S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15970_20_22508288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15B78103-EFD9-470B-9216-A0EB1B54CED0</gtr:id><gtr:title>Regulatory T-cell directed therapies in liver diseases.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_15970_013_05_034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D3CDCD5-E054-46D0-8359-EF73CBB86F6B</gtr:id><gtr:title>Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1714d2e8e641f60c88320a124f70ca1"><gtr:id>d1714d2e8e641f60c88320a124f70ca1</gtr:id><gtr:otherNames>Li KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dd975a9136e8.26952083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF93C705-0029-470E-8227-1994830BCE9F</gtr:id><gtr:title>HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58bd4736c6e304.50229515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6C1B953-E706-4FC7-9C69-A807C818CFD1</gtr:id><gtr:title>Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5472b5a49c91cddc873d38fbc2a2e985"><gtr:id>5472b5a49c91cddc873d38fbc2a2e985</gtr:id><gtr:otherNames>Arends P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>545a5b3eb8f660.47494684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFA012A5-FB5E-478A-99FB-7E2CBC3B706D</gtr:id><gtr:title>MAIT cells are activated during human viral infections.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd9c5d3ad67e5b8adc8f4409ebdea785"><gtr:id>fd9c5d3ad67e5b8adc8f4409ebdea785</gtr:id><gtr:otherNames>van Wilgenburg B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58bd478e3bcb04.68990755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CEA9595-956D-4B5E-B5AF-90A02013AD62</gtr:id><gtr:title>Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a98943a976199c6e20d1fb494d7cffb"><gtr:id>0a98943a976199c6e20d1fb494d7cffb</gtr:id><gtr:otherNames>Coombes JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>545a5bb6565f52.13261287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A838EAEA-BA53-475A-ABE6-455304DD8CD4</gtr:id><gtr:title>Management of patients with difficult autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-283X</gtr:issn><gtr:outcomeId>pm_15970_20_23152735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70A02B70-40C7-4CA6-9680-81E56D6F2C99</gtr:id><gtr:title>Regulatory T cells and autoimmune hepatitis: defective cells or a hostile environment?</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15970_20_22522382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EF87857-ED2B-40E9-A640-D9EDEC70958F</gtr:id><gtr:title>Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2ec17573a7d601b84c252ca07eecde4"><gtr:id>e2ec17573a7d601b84c252ca07eecde4</gtr:id><gtr:otherNames>Liaskou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15970_20_22911542</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3718FA57-9114-4B3B-B083-3172A12E7CFA</gtr:id><gtr:title>Low-dose interleukin-2 and HCV-induced vasculitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15970_20_22475612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5288D3F7-CA37-4509-A7CB-838948FD5D0E</gtr:id><gtr:title>The regulation of T-cell recruitment to the human liver during acute liver failure.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fb0670214d5bc63d29e42ea5eab49fb"><gtr:id>6fb0670214d5bc63d29e42ea5eab49fb</gtr:id><gtr:otherNames>Tuncer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>doi_15970__liv_12182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1433D7F2-88D8-47D8-88C0-17353C4CEE53</gtr:id><gtr:title>Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84fcea8d3b0649ebc2a5600412a364bb"><gtr:id>84fcea8d3b0649ebc2a5600412a364bb</gtr:id><gtr:otherNames>Than NN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-5521</gtr:issn><gtr:outcomeId>56dd975a51e183.00187430</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>795C8077-81F2-4132-B20B-30DC1A1B7AD9</gtr:id><gtr:title>Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b3c24374de29dcc05c743f4538117cb"><gtr:id>9b3c24374de29dcc05c743f4538117cb</gtr:id><gtr:otherNames>Chen YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dd97590cb087.38205187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFB9DF57-CB25-40C3-B41A-2B81EA3C9136</gtr:id><gtr:title>Vascular cell adhesion molecule 1 expression by biliary epithelium promotes persistence of inflammation by inhibiting effector T-cell apoptosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c09ab949db1e04a2c7b6f1ec3230524"><gtr:id>2c09ab949db1e04a2c7b6f1ec3230524</gtr:id><gtr:otherNames>Afford SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>545a5b0fd20814.50750972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47B4D1FB-1257-4A11-8EE9-9B59D0EE9060</gtr:id><gtr:title>Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8724d15d220ee3f638455f4fd50a38f1"><gtr:id>8724d15d220ee3f638455f4fd50a38f1</gtr:id><gtr:otherNames>H?bener S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>56dd9759f22493.13867068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA91FA46-3E07-4E33-AC7C-0E86D140880F</gtr:id><gtr:title>Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dd975963c064.61428389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54BE46C6-3B1F-40E5-834F-DAADA9AC80EA</gtr:id><gtr:title>Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1</gtr:title><gtr:parentPublicationTitle>JOURNAL OF HEPATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca0a8ca501baceb88aa818c2a0fe300c"><gtr:id>ca0a8ca501baceb88aa818c2a0fe300c</gtr:id><gtr:otherNames>Jeffery Hannah C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>585d6a3377fd66.99234621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C76D4AF-49FE-45E1-8E65-409AC993CCC8</gtr:id><gtr:title>Rapid recovery of cytochrome P450 3A4 after protease inhibitor withdrawal in post-liver transplant patients.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/736816f8f545c53af3577861e58e44cd"><gtr:id>736816f8f545c53af3577861e58e44cd</gtr:id><gtr:otherNames>Oo YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>pm_15970_20_22740311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8E79679-DA41-4A4F-8D0C-604B3540BEE3</gtr:id><gtr:title>Autoimmune hepatitis: an approach to disease understanding and management.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31fc28eeeddbd4b9de542f9d897f69d9"><gtr:id>31fc28eeeddbd4b9de542f9d897f69d9</gtr:id><gtr:otherNames>Corrigan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>56dd975ab1a015.37445932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A78F575A-3CFE-4DA7-A0C7-7AA82BDD2A5E</gtr:id><gtr:title>Regulatory T Cell Metabolism in the Hepatic Microenvironment.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7182140a99c2dbbdb2e027e47d34dec"><gtr:id>a7182140a99c2dbbdb2e027e47d34dec</gtr:id><gtr:otherNames>Wawman RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a67956307b812.80796763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>985A690C-DB84-4957-9385-A464B2A991E2</gtr:id><gtr:title>Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a6781936cffd9.14031206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CBB41C0-C288-43C7-A9A6-636D876B1701</gtr:id><gtr:title>Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis</gtr:title><gtr:parentPublicationTitle>Hepatology Communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84c98eb29d3d8c9ae1a83f1e94e27b04"><gtr:id>84c98eb29d3d8c9ae1a83f1e94e27b04</gtr:id><gtr:otherNames>Jeffery H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a995f5cdae847.61993129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B16DBED1-425D-4457-8888-B569FE537A7E</gtr:id><gtr:title>Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a98943a976199c6e20d1fb494d7cffb"><gtr:id>0a98943a976199c6e20d1fb494d7cffb</gtr:id><gtr:otherNames>Coombes JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56dd9759c64115.30166247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1675A861-E7C4-475A-994F-E0F7620A2B16</gtr:id><gtr:title>Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>585d4019e49186.69036447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A1C0682-269F-4488-BE3B-7CE9B364D34D</gtr:id><gtr:title>Flares during long-term entecavir therapy in chronic hepatitis B.</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology and hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bb19ae06ee1e2e42b2b590c7c326813"><gtr:id>5bb19ae06ee1e2e42b2b590c7c326813</gtr:id><gtr:otherNames>Chi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0815-9319</gtr:issn><gtr:outcomeId>58bd47c9756f53.72868191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>863DA226-055B-4656-B756-E24E48188AC5</gtr:id><gtr:title>Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/831e3872a69b1eb56f7b45f7845ce099"><gtr:id>831e3872a69b1eb56f7b45f7845ce099</gtr:id><gtr:otherNames>Webb G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dd97593d9818.77417108</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002552</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>